<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03428568</url>
  </required_header>
  <id_info>
    <org_study_id>RC15/152/R</org_study_id>
    <nct_id>NCT03428568</nct_id>
  </id_info>
  <brief_title>Safety Trial of Herbal Melanin in Gastritis Patients</brief_title>
  <acronym>RASATHEME</acronym>
  <official_title>Open Label, Randomized, Single Site Clinical Trial To Compare The Safety Of Herbal Melanin Extracted From Nigella Sativa Seeds Vs Standard Of Care Treatment In Treating Gastritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Abdullah International Medical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Abdullah International Medical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to use Melanole, a herbal extract from Nigella sativa, for treatment
      of gastritis. The effect of Melanole will be compared between participants (including H.
      pylori and non-H.pylori infected patients), with the triple therapy and Standard of care
      treatment of gastritis, respectively.

      All participants will be examined before and after the administration of Melanole. The
      results showing a relief of gastritis symptoms for non-H. pylori patients and partial or
      complete eradication of H. pylori for H.pylori infected patients will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      The melanin to be used in this study is a herbal melanin (HM) that has been extracted from
      the plant Nigella sativa. Nigella sativa was obtained from local market in Riyadh, Saudi
      Arabia. HM has been obtained from seed total powdered extract using standard extraction
      procedure and has been reported as a patent for the first time.The percentage of pure melanin
      in total Nigella sativa L. is 9% as identified using Electron Spin Resonance (ESR) and
      Fourier Transform- Infra Red (FI-IR) and calculated using wet chemical methods. Three
      different patches of Nigella sativa L that were obtained from different Nigella sativa L
      species were tested (Saudi, Ethiopian and Indian) and the same percentage of HM was obtained.
      The safety of HM has been tested and confirmed by different labs including lab for Quality
      and Safety and Industrial Research Institute(IRI) (see supplements 1 and 2). Similarly, the
      safety of the HM capsules have been tested at the Toxicology and Bioanalysis in King Faisal
      Specialist Hospital(KFSH) (see supplement 3). Moreover, the capsules have been approved and
      certified for free sale by the Ministry of Health at Lebanon.

      Study Area:

      The study will be performed in the gastroenterology clinic at National Guard Health
      Affairs(NGHA). Volunteers who participate in the study will be recruited from NGHA clinics.
      Participates are patients diagnosed with gastritis, both H. Pylori and non-H.Pylori infected,
      together with healthy volunteers.

      The histological studies will be performed at the pathology department at NGHA.

      Taking biopsies during endoscopy:

      The best way to get tissue samples from the stomach is through a procedure called an
      esophagogastroduodenoscopy. It is more commonly known as an endoscopy or EGD. This is
      generally done as an outpatient procedure. The biopsies will be taken through the
      esophagogastroduodenoscopy (EGD) by a ultra-thin forceps, then will be saved in special
      container and send to the Laboratory for staining and microscopic examination. Under the
      microscope the pathologist will look for the abnormal mucosa , inflammation, ulceration , and
      helicobacter pylori gram negative micro-organism .During the procedure there is low chance of
      some complications which happened in 1: 10 000 , these include ; injury to the mucosa with
      bleeding and perforation , discomfort , sedation related complication like headache and
      nausea . These rare but the patient will be informed about it.

      Study Subjects:

      Patients with gastritis or showing gastritis symptoms will be enrolled in this study.
      Gastritis participate patients will be selected after detection of gastric lesions by
      undergoing routine diagnostic tests (such as endoscopy of upper digestive system).

      Sample Size Calculation and Estimation:

      The sample size has been estimated as 132 ( 22 subjects per group). The calculation and
      estimation have been done as follows:

      Sample Size Calculation

      The calculation of sample size was performed using Query Advisor V.7

      Sample Size Estimated

      The minimum number of Subjects needed in each group is 18, a two sided 95.0% confidence
      interval for the difference between a Group 1 proportion of 0.6 and Group 2 proportion of 0.2
      based on the large sample normal approximation will extend 0.3 from the observed differences
      in proportions. The total required sample would be (6 groups x 18=108).The assumed
      withdrawal/dropout rate is 20% in each group (22 subjects per group), the final sample size
      would ne 132 subjects. The calculation of sample size was performed using Query Advisor V.7)

      Data Collection method:

      All data will be collected electronically and reported in Case Report Forms.

      Data Cleaning:

      Raw data will be processed in accordance with the best practices for raw data management to
      identify any inaccuracies or incompleteness in advance to the statistical analysis. In order
      to accomplish this task, all interval variables will be checked and summarized in terms of
      maximum and minimum values. Minimum and maximum values will be checked and compared against
      the nominal maximum and minimum value of each variable and variables with implausible values
      will be flagged. A similar process will be applied to categorical variables to identify any
      potential anomalies (miscode) by running a general frequency analysis.

      Cohort Characterization:

      All variables will be summarized and reported using descriptive statistics. Interval
      variables will be summarized and reported in terms of mean and standard deviation.
      Categorical variables will be summarized and reported in terms of frequency distribution. All
      variables will be compared across study groups using chi square and t test accordingly.

      Primary Outcome(s) Analysis:

      Chi square test will be used to compare the distribution of gastritis across the study
      groups. Results will be reported in terms of count, percent, and p-value. Significance will
      be declared at alfa less than 0.05. Binary logistic regression will be used to identify
      significant predictors of the primary outcomes. The statistical model will include key
      variables that showed significance with the primary outcome at the bivariate level. Results
      will be reported in terms of odds ratio, std. error, 95% confidence interval, and p-value.
      Significance will be declared at alfa less than 0.05.

      Intent to treat analysis will be the approach in analyzing the data.

      Statistical Analytical System(SAS) 9.2 will be used for all statistical analyses.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants cured from acidity symptoms and H.Pylori -induced gastritis</measure>
    <time_frame>6 months</time_frame>
    <description>Investigators hypothesize that HM is an effective candidate that can decrease stomach acidity and eradicate H.Pylori by working as Proton Pump Inhibitor(PPI) and/or antibacterial agent, respectively. Investigators suggest the role of HM in activation of Toll like Receptor 4 (TLR4)/Cycloxygenase2(COX2)/ProstaglandinE2( PGE2) as one underlying mechanism.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants cured with herbal melanin as compared to number of participants cured with standard of care for gastritis and H.Pylori-induced gastritis</measure>
    <time_frame>6 months</time_frame>
    <description>Gastritis as indicated by improving the clinical presentation of gastritis and confirmed by end of treatment endoscopy and stool antigen test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants between study groups having high expression of TLR4 and COX2 as assessed by Western blots procedure.</measure>
    <time_frame>6 months</time_frame>
    <description>By using stomach biopsies for measuring the expression of TLR4 and COX 2 expression.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Acid Dyspepsia</condition>
  <condition>Gastritis</condition>
  <arm_group>
    <arm_group_label>Herbal Melanin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herbal melanin 1800 milligram(mg) orally thrice a day with meals (300mgx2 capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nexium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>omeprazole 40 mg once per day for one month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H-Pylori infected : Herbal Melanin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herbal melanin 1800 mg orally thrice a day(TID) with meals (300 mg x2 capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nexium+ amoxil+clarithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>omeprazole40 mg P.O. Twice per Day(BID) for one month + Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks.
Omeprazole+Amoxil+clarithromycin is the standard triple therapy given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nexium +Herbal melanin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omeprazole 40 mg P.O. BID for one month +1800 mg Herbal melanin PO TID (300mg x2 capsules) Omeprazole + Herbal melanin will be tested</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herbal melanin+amoxil+ clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks +1800 mg Herbal melanin PO TID(300 mg X 2 capsules) Herbal melanin+Amoxil+Clarithromycin will be tested</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Herbal Melanin</intervention_name>
    <description>Herbal melanin extracted from Nigella sativa seeds</description>
    <arm_group_label>Herbal Melanin</arm_group_label>
    <arm_group_label>H-Pylori infected : Herbal Melanin</arm_group_label>
    <arm_group_label>nexium +Herbal melanin</arm_group_label>
    <arm_group_label>Herbal melanin+amoxil+ clarithromycin</arm_group_label>
    <other_name>Melanole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexium</intervention_name>
    <description>omeprazole</description>
    <arm_group_label>Nexium</arm_group_label>
    <arm_group_label>nexium+ amoxil+clarithromycin</arm_group_label>
    <arm_group_label>nexium +Herbal melanin</arm_group_label>
    <other_name>Aciloc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxil</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>nexium+ amoxil+clarithromycin</arm_group_label>
    <arm_group_label>Herbal melanin+amoxil+ clarithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>nexium+ amoxil+clarithromycin</arm_group_label>
    <arm_group_label>Herbal melanin+amoxil+ clarithromycin</arm_group_label>
    <other_name>Klacid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or Females between 18- 60 years

          -  Willing to sign Informed Consent Form (ICF)

          -  Women of Child bearing age will be asked to conduct a pregnancy test before enrolling
             in the study and offered contraceptives for the duration of the study participation

          -  Clinical Pictures of Gastritis.

          -  Histologically confirmed H- Pylori Gastritis or Non H- Pylori by one week from
             enrollment.

        Exclusion Criteria:

          -  Patients with disturbed gastrointestinal physiology (gastric surgery, vagotomy,
             Zollinger-Ellison syndrome)

          -  Patients who have been treated with proton pump inhibitors during 3 weeks prior to
             inclusion

          -  Patients who have been treated with antibiotics or bismuth containing drugs 1 month
             prior enrolling in the study

          -  Patient with pyloric stenosis

          -  Patient with Hematologic disorder

          -  Patient with congestive heart disease

          -  Women who are pregnant or lactating

          -  Current or past history of malignancy

          -  Drug abuser and chronic alcoholism

          -  Patients currently participating in any other clinical trial of any kind
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adila SA Elobeid, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of National Guard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adila SA Elobeid, PhD</last_name>
    <phone>+966553543096</phone>
    <email>adilasalihelobeid@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>khizra sultana, Masters</last_name>
    <phone>+966542403883</phone>
    <email>khizzy31@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>El-Obeid A, Al-Harbi S, Al-Jomah N, Hassib A. Herbal melanin modulates tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) production. Phytomedicine. 2006 May;13(5):324-33. Epub 2005 Sep 19.</citation>
    <PMID>16635740</PMID>
  </reference>
  <reference>
    <citation>Biotechnological Method for Production of Melanin Pigments. Patent, award by Swedish PRV Patent office-Stockholm 2011 and United Nations PCT-WIPO 2011. Registered in US &amp;Canada</citation>
  </reference>
  <reference>
    <citation>Extraction of melanin from Nigella sativa L. Patent No. 451, Khartoum, Sudan. 1998.</citation>
  </reference>
  <reference>
    <citation>Tortora, G.J. and Grabowski, S.R. (2003). Principles of Anatomy and Physiology. 10th ed. John Wiley&amp; Sons, Inc, NJ, p.889.).</citation>
  </reference>
  <reference>
    <citation>Parkin DM. International variation. Oncogene. 2004 Aug 23;23(38):6329-40. Review.</citation>
    <PMID>15322508</PMID>
  </reference>
  <reference>
    <citation>Peleteiro B, Bastos A, Ferro A, Lunet N. Erratum to: Prevalence of Helicobacter pylori Infection Worldwide: A Systematic Review of Studies with National Coverage. Dig Dis Sci. 2015 Sep;60(9):2849. doi: 10.1007/s10620-015-3779-5.</citation>
    <PMID>26160435</PMID>
  </reference>
  <reference>
    <citation>Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol. 2014 Feb 14;20(6):1450-69. doi: 10.3748/wjg.v20.i6.1450. Review.</citation>
    <PMID>24587621</PMID>
  </reference>
  <reference>
    <citation>Hawkins C, Hanks GW. The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs: a review of the literature. J Pain Symptom Manage. 2000 Aug;20(2):140-51. Review.</citation>
    <PMID>10989252</PMID>
  </reference>
  <reference>
    <citation>El-Tahir, K. E. H.; Hassib, A. M.; El-Hag, H.; Ponten, F.; Westermark, B. El- Obeid Adila (2009). Anti-ulcerogenic effects of Nigella sativa Melanin. Sudan Patent No. 1683.</citation>
  </reference>
  <reference>
    <citation>Mimura T, Maeda K, Tsujibo H, Satake M, Fujita T. Studies on biological activities of melanin from marine animals. II. Purification of melanin from Octopus vulgaris Cuvier and its inhibitory activity on gastric juice secretion in rats. Chem Pharm Bull (Tokyo). 1982 Apr;30(4):1508-12.</citation>
    <PMID>7105266</PMID>
  </reference>
  <reference>
    <citation>Mimura T, Maeda K, Terada T, Oda Y, Morishita K, Aonuma S. Studies on biological activities of melanin from marine animals. III. Inhibitory effect of SM II (low molecular weight melanoprotein from squid) on phenylbutazone-induced ulceration in gastric mucosa in rats, and its mechanism of action. Chem Pharm Bull (Tokyo). 1985 May;33(5):2052-60.</citation>
    <PMID>4053227</PMID>
  </reference>
  <reference>
    <citation>El-Dakhakhny M, Barakat M, El-Halim MA, Aly SM. Effects of Nigella sativa oil on gastric secretion and ethanol induced ulcer in rats. J Ethnopharmacol. 2000 Sep;72(1-2):299-304.</citation>
    <PMID>10967486</PMID>
  </reference>
  <reference>
    <citation>Kanter M, Demir H, Karakaya C, Ozbek H. Gastroprotective activity of Nigella sativa L oil and its constituent, thymoquinone against acute alcohol-induced gastric mucosal injury in rats. World J Gastroenterol. 2005 Nov 14;11(42):6662-6.</citation>
    <PMID>16425361</PMID>
  </reference>
  <reference>
    <citation>Seniuk OF, Gorovoj LF, Beketova GV, Savichuk HO, Rytik PG, Kucherov II, Prilutskay AB, Prilutsky AI. Anti-infective properties of the melanin-glucan complex obtained from medicinal tinder bracket mushroom, Fomes fomentarius (L.: Fr.) Fr. (Aphyllophoromycetideae). Int J Med Mushrooms. 2011;13(1):7-18.</citation>
    <PMID>22135899</PMID>
  </reference>
  <reference>
    <citation>Peterson WL. The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997 Apr;11 Suppl 1:21-5. Review.</citation>
    <PMID>9146787</PMID>
  </reference>
  <reference>
    <citation>Salem EM, Yar T, Bamosa AO, Al-Quorain A, Yasawy MI, Alsulaiman RM, Randhawa MA. Comparative study of Nigella Sativa and triple therapy in eradication of Helicobacter Pylori in patients with non-ulcer dyspepsia. Saudi J Gastroenterol. 2010 Jul-Sep;16(3):207-14. doi: 10.4103/1319-3767.65201.</citation>
    <PMID>20616418</PMID>
  </reference>
  <reference>
    <citation>Poelmans J, Feenstra L, Demedts I, Rutgeerts P, Tack J. The yield of upper gastrointestinal endoscopy in patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am J Gastroenterol. 2004 Aug;99(8):1419-26.</citation>
    <PMID>15307853</PMID>
  </reference>
  <reference>
    <citation>Poelmans J, Tack J, Feenstra L. Chronic middle ear disease and gastroesophageal reflux disease: a causal relation? Otol Neurotol. 2001 Jul;22(4):447-50.</citation>
    <PMID>11449097</PMID>
  </reference>
  <reference>
    <citation>Poelmans J, Feenstra L, Tack J. Determinants of long-term outcome of patients with reflux-related ear, nose, and throat symptoms. Dig Dis Sci. 2006 Feb;51(2):282-8.</citation>
    <PMID>16534670</PMID>
  </reference>
  <reference>
    <citation>Schmausser B, Andrulis M, Endrich S, Müller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol. 2005 Jun;295(3):179-85.</citation>
    <PMID>16044857</PMID>
  </reference>
  <reference>
    <citation>Schmausser B, Andrulis M, Endrich S, Lee SK, Josenhans C, Müller-Hermelink HK, Eck M. Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol. 2004 Jun;136(3):521-6.</citation>
    <PMID>15147355</PMID>
  </reference>
  <reference>
    <citation>El-Obeid A, Hassib A, Pontén F, Westermark B. Effect of herbal melanin on IL-8: a possible role of Toll-like receptor 4 (TLR4). Biochem Biophys Res Commun. 2006 Jun 16;344(4):1200-6. Epub 2006 May 2.</citation>
    <PMID>16650380</PMID>
  </reference>
  <reference>
    <citation>Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004 Jul 23;118(2):229-41.</citation>
    <PMID>15260992</PMID>
  </reference>
  <reference>
    <citation>Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, Xu R, Inoue H, Arditi M, Dannenberg AJ, Abreu MT. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology. 2006 Sep;131(3):862-77.</citation>
    <PMID>16952555</PMID>
  </reference>
  <reference>
    <citation>Zheng L, Riehl TE, Stenson WF. Regulation of colonic epithelial repair in mice by Toll-like receptors and hyaluronic acid. Gastroenterology. 2009 Dec;137(6):2041-51. doi: 10.1053/j.gastro.2009.08.055. Epub 2009 Sep 2.</citation>
    <PMID>19732774</PMID>
  </reference>
  <reference>
    <citation>Hoogerwerf et al. 2006. Hoogerwerf, W.J., Pasricha, P.J., 2006. Pharmacotherapy of gastric acidity,peptic ulcer and gastroesophageal reflux disease: Goodman and Gilman's.The pharmacological basis of therapeutics. McGraw-Hill, United States, pp.869-882).</citation>
  </reference>
  <reference>
    <citation>Wada A, Ogushi K, Kimura T, Hojo H, Mori N, Suzuki S, Kumatori A, Se M, Nakahara Y, Nakamura M, Moss J, Hirayama T. Helicobacter pylori-mediated transcriptional regulation of the human beta-defensin 2 gene requires NF-kappaB. Cell Microbiol. 2001 Feb;3(2):115-23.</citation>
    <PMID>11207625</PMID>
  </reference>
  <reference>
    <citation>Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science. 2002 Nov 1;298(5595):1025-9.</citation>
    <PMID>12411706</PMID>
  </reference>
  <reference>
    <citation>Ohara T, Morishita T, Suzuki H, Masaoka T, Nagata H, Hibi T. Pathophysiological role of human beta-defensins 2 in gastric mucosa. Int J Mol Med. 2004 Dec;14(6):1023-7.</citation>
    <PMID>15547668</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>February 4, 2018</last_update_submitted>
  <last_update_submitted_qc>February 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herbal Melanin</keyword>
  <keyword>H.Pylori</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

